ID   IRAK4_HUMAN             Reviewed;         460 AA.
AC   Q9NWZ3; Q69FE1; Q8TDF7; Q9Y589;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Interleukin-1 receptor-associated kinase 4;
DE            Short=IRAK-4;
DE            EC=2.7.11.1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-64;
GN   Name=IRAK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND INTERACTION WITH
RP   IRAK1 AND TRAF6.
RX   PubMed=11960013; DOI=10.1073/pnas.082100399;
RA   Li S., Strelow A., Fontana E.J., Wesche H.;
RT   "IRAK4: a novel member of the IRAK family with the properties of an
RT   IRAK-kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5567-5572(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND IDENTIFICATION AS A RENAL
RP   CANCER ANTIGEN.
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Spleen;
RA   Chuang T.H., Ulevitch R.J.;
RT   "Human interleukin-1 receptor associated kinase 4 cDNA sequences.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-98; ARG-390 AND
RP   THR-428.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH IRAK1; PELI1 AND TRAF6.
RX   PubMed=12496252; DOI=10.1074/jbc.M212112200;
RA   Jiang Z., Johnson H.J., Nie H., Qin J., Bird T.A., Li X.;
RT   "Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling
RT   through its interaction with the IL-1 receptor-associated kinase 4
RT   (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6
RT   (TRAF6) complex.";
RL   J. Biol. Chem. 278:10952-10956(2003).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF IRAK1.
RX   PubMed=12538665; DOI=10.1084/jem.20021790;
RA   Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.;
RT   "Inhibition of interleukin 1 receptor/Toll-like receptor signaling
RT   through the alternatively spliced, short form of MyD88 is due to its
RT   failure to recruit IRAK-4.";
RL   J. Exp. Med. 197:263-268(2003).
RN   [10]
RP   INVOLVEMENT IN IRAK4D.
RX   PubMed=12925671; DOI=10.1084/jem.20030701;
RA   Medvedev A.E., Lentschat A., Kuhns D.B., Blanco J.C.G., Salkowski C.,
RA   Zhang S., Arditi M., Gallin J.I., Vogel S.N.;
RT   "Distinct mutations in IRAK-4 confer hyporesponsiveness to
RT   lipopolysaccharide and interleukin-1 in a patient with recurrent
RT   bacterial infections.";
RL   J. Exp. Med. 198:521-531(2003).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF LYS-213.
RX   PubMed=15084582; DOI=10.1074/jbc.M400785200;
RA   Qin J., Jiang Z., Qian Y., Casanova J.-L., Li X.;
RT   "IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-
RT   associated kinase phosphorylation and IL-1 responsiveness.";
RL   J. Biol. Chem. 279:26748-26753(2004).
RN   [12]
RP   INVOLVEMENT IN IRAK4D.
RX   PubMed=12637671; DOI=10.1126/science.1081902;
RA   Picard C., Puel A., Bonnet M., Ku C.-L., Bustamante J., Yang K.,
RA   Soudais C., Dupuis S., Feinberg J., Fieschi C., Elbim C.,
RA   Hitchcock R., Lammas D., Davies G., Al-Ghonaium A., Al-Rayes H.,
RA   Al-Jumaah S., Al-Hajjar S., Al-Mohsen I.Z., Frayha H.H., Rucker R.,
RA   Hawn T.R., Aderem A., Tufenkeji H., Haraguchi S., Day N.K., Good R.A.,
RA   Gougerot-Pocidalo M.-A., Ozinsky A., Casanova J.-L.;
RT   "Pyogenic bacterial infections in humans with IRAK-4 deficiency.";
RL   Science 299:2076-2079(2003).
RN   [13]
RP   INTERACTION WITH IL1RL1.
RX   PubMed=16286016; DOI=10.1016/j.immuni.2005.09.015;
RA   Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K.,
RA   Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F.,
RA   Kastelein R.A.;
RT   "IL-33, an interleukin-1-like cytokine that signals via the IL-1
RT   receptor-related protein ST 2 and induces T helper type 2-associated
RT   cytokines.";
RL   Immunity 23:479-490(2005).
RN   [14]
RP   IDENTIFICATION IN COMPLEX WITH IRAK1; MYD88; PELI1 AND TRAF6.
RX   PubMed=16951688; DOI=10.1038/ni1383;
RA   Choi K.C., Lee Y.S., Lim S., Choi H.K., Lee C.H., Lee E.K., Hong S.,
RA   Kim I.H., Kim S.J., Park S.H.;
RT   "Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor
RT   signaling through direct interaction with the adaptor Pellino-1.";
RL   Nat. Immunol. 7:1057-1065(2006).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF NCF1.
RX   PubMed=17217339; DOI=10.1042/BJ20061184;
RA   Pacquelet S., Johnson J.L., Ellis B.A., Brzezinska A.A., Lane W.S.,
RA   Munafo D.B., Catz S.D.;
RT   "Cross-talk between IRAK-4 and the NADPH oxidase.";
RL   Biochem. J. 403:451-461(2007).
RN   [16]
RP   FUNCTION IN TLR7 SIGNALING PATHWAY.
RX   PubMed=17337443; DOI=10.1074/jbc.M700548200;
RA   Koziczak-Holbro M., Joyce C., Gluck A., Kinzel B., Muller M.,
RA   Tschopp C., Mathison J.C., Davis C.N., Gram H.;
RT   "IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor-
RT   and toll-like receptor 7-mediated signaling and gene expression.";
RL   J. Biol. Chem. 282:13552-13560(2007).
RN   [17]
RP   INVOLVEMENT IN IPD1.
RX   PubMed=16950813; DOI=10.1136/jmg.2006.044446;
RA   Ku C.-L., Picard C., Erdos M., Jeurissen A., Bustamante J., Puel A.,
RA   von Bernuth H., Filipe-Santos O., Chang H.-H., Lawrence T., Raes M.,
RA   Marodi L., Bossuyt X., Casanova J.-L.;
RT   "IRAK4 and NEMO mutations in otherwise healthy children with recurrent
RT   invasive pneumococcal disease.";
RL   J. Med. Genet. 44:16-23(2007).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF PELI1.
RX   PubMed=17997719; DOI=10.1042/BJ20071365;
RA   Ordureau A., Smith H., Windheim M., Peggie M., Carrick E., Morrice N.,
RA   Cohen P.;
RT   "The IRAK-catalysed activation of the E3 ligase function of Pellino
RT   isoforms induces the Lys63-linked polyubiquitination of IRAK1.";
RL   Biochem. J. 409:43-52(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-34, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP.
RX   PubMed=20400509; DOI=10.1074/jbc.M109.098137;
RA   Dunne A., Carpenter S., Brikos C., Gray P., Strelow A., Wesche H.,
RA   Morrice N., O'Neill L.A.;
RT   "IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and
RT   degradation of MyD88 adaptor-like (Mal).";
RL   J. Biol. Chem. 285:18276-18282(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21325272; DOI=10.1074/jbc.M110.199653;
RA   Nagpal K., Plantinga T.S., Sirois C.M., Monks B.G., Latz E.,
RA   Netea M.G., Golenbock D.T.;
RT   "Natural loss-of-function mutation of myeloid differentiation protein
RT   88 disrupts its ability to form Myddosomes.";
RL   J. Biol. Chem. 286:11875-11882(2011).
RN   [27]
RP   REVIEW ON MYDDOSOME.
RX   PubMed=21269878; DOI=10.1016/j.it.2010.12.005;
RA   Gay N.J., Gangloff M., O'Neill L.A.;
RT   "What the Myddosome structure tells us about the initiation of innate
RT   immunity.";
RL   Trends Immunol. 32:104-109(2011).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 154-460 IN COMPLEX WITH
RP   INHIBITORS, AND PHOSPHORYLATION AT THR-345 AND SER-346.
RX   PubMed=17161373; DOI=10.1016/j.str.2006.11.001;
RA   Wang Z., Liu J., Sudom A., Ayres M., Li S., Wesche H., Powers J.P.,
RA   Walker N.P.C.;
RT   "Crystal structures of IRAK-4 kinase in complex with inhibitors: a
RT   serine/threonine kinase with tyrosine as a gatekeeper.";
RL   Structure 14:1835-1844(2006).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 163-460, AND PHOSPHORYLATION
RP   AT THR-342 AND THR-345.
RA   Mol C.D., Arduini R.M., Baker D.P., Chien E.Y., Dougan D.R.,
RA   Friedman J., Gibaja V., Hession C.A., Horne A.;
RT   "Crystal structures of the apo and inhibited IRAK4 kinase domain.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 160-460 IN COMPLEX WITH ATP
RP   ANALOGS, PHOSPHORYLATION AT THR-342; THR-345 AND SER-346, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17312103; DOI=10.4049/jimmunol.178.5.2641;
RA   Kuglstatter A., Villasenor A.G., Shaw D., Lee S.W., Tsing S., Niu L.,
RA   Song K.W., Barnett J.W., Browner M.F.;
RT   "Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal
RT   novel features and multiple conformations.";
RL   J. Immunol. 178:2641-2645(2007).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (3.40 ANGSTROMS) OF 4-106.
RX   PubMed=20485341; DOI=10.1038/nature09121;
RA   Lin S.-C., Lo Y.-C., Wu H.;
RT   "Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R
RT   signalling.";
RL   Nature 465:885-890(2010).
RN   [34]
RP   VARIANT IRAK4D CYS-12, CHARACTERIZATION OF VARIANT IRAK4D CYS-12,
RP   VARIANT HIS-391, AND FUNCTION.
RX   PubMed=17878374; DOI=10.4049/jimmunol.179.7.4754;
RA   Hoarau C., Gerard B., Lescanne E., Henry D., Francois S.,
RA   Lacapere J.J., El Benna J., Dang P.M., Grandchamp B., Lebranchu Y.,
RA   Gougerot-Pocidalo M.A., Elbim C.;
RT   "TLR9 activation induces normal neutrophil responses in a child with
RT   IRAK-4 deficiency: involvement of the direct PI3K pathway.";
RL   J. Immunol. 179:4754-4765(2007).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-5; VAL-355; HIS-391 AND THR-428.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [36]
RP   VARIANT IRAK4D ASP-298, AND CHARACTERIZATION OF VARIANT IRAK4D
RP   ASP-298.
RX   PubMed=19663824; DOI=10.1111/j.1365-2141.2009.07838.x;
RA   Bouma G., Doffinger R., Patel S.Y., Peskett E., Sinclair J.C.,
RA   Barcenas-Morales G., Cerron-Gutierrez L., Kumararatne D.S.,
RA   Davies E.G., Thrasher A.J., Burns S.O.;
RT   "Impaired neutrophil migration and phagocytosis in IRAK-4
RT   deficiency.";
RL   Br. J. Haematol. 147:153-156(2009).
RN   [37]
RP   INVOLVEMENT IN IRAK4D, AND VARIANT IRAK4D ASP-298.
RX   PubMed=21057262; DOI=10.1097/MD.0b013e3181fd8ec3;
RA   Picard C., von Bernuth H., Ghandil P., Chrabieh M., Levy O.,
RA   Arkwright P.D., McDonald D., Geha R.S., Takada H., Krause J.C.,
RA   Creech C.B., Ku C.L., Ehl S., Marodi L., Al-Muhsen S., Al-Hajjar S.,
RA   Al-Ghonaium A., Day-Good N.K., Holland S.M., Gallin J.I., Chapel H.,
RA   Speert D.P., Rodriguez-Gallego C., Colino E., Garty B.Z., Roifman C.,
RA   Hara T., Yoshikawa H., Nonoyama S., Domachowske J., Issekutz A.C.,
RA   Tang M., Smart J., Zitnik S.E., Hoarau C., Kumararatne D.S.,
RA   Thrasher A.J., Davies E.G., Bethune C., Sirvent N., de Ricaud D.,
RA   Camcioglu Y., Vasconcelos J., Guedes M., Vitor A.B., Rodrigo C.,
RA   Almazan F., Mendez M., Arostegui J.I., Alsina L., Fortuny C.,
RA   Reichenbach J., Verbsky J.W., Bossuyt X., Doffinger R., Abel L.,
RA   Puel A., Casanova J.L.;
RT   "Clinical features and outcome of patients with IRAK-4 and MyD88
RT   deficiency.";
RL   Medicine (Baltimore) 89:403-425(2010).
RN   [38]
RP   CHARACTERIZATION OF VARIANTS VAL-5; TRP-20; THR-26; VAL-39 AND ARG-98,
RP   CHARACTERIZATION OF VARIANTS IRAK4D CYS-12 AND ASP-298, FUNCTION, AND
RP   INTERACTION WITH MYD88.
RX   PubMed=24316379; DOI=10.1016/j.molimm.2013.11.008;
RA   Yamamoto T., Tsutsumi N., Tochio H., Ohnishi H., Kubota K., Kato Z.,
RA   Shirakawa M., Kondo N.;
RT   "Functional assessment of the mutational effects of human IRAK4 and
RT   MyD88 genes.";
RL   Mol. Immunol. 58:66-76(2014).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a critical
CC       role in initiating innate immune response against foreign
CC       pathogens. Involved in Toll-like receptor (TLR) and IL-1R
CC       signaling pathways (PubMed:17878374). Is rapidly recruited by
CC       MYD88 to the receptor-signaling complex upon TLR activation to
CC       form the Myddosome together with IRAK2. Phosphorylates initially
CC       IRAK1, thus stimulating the kinase activity and intensive
CC       autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases
CC       Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-
CC       mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding
CC       domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing
CC       together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-
CC       IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and
CC       IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and
CC       activation. Alternatively, phosphorylates TIRAP to promote its
CC       ubiquitination and subsequent degradation. Phosphorylates NCF1 and
CC       regulates NADPH oxidase activation after LPS stimulation
CC       suggesting a similar mechanism during microbial infections.
CC       {ECO:0000269|PubMed:11960013, ECO:0000269|PubMed:12538665,
CC       ECO:0000269|PubMed:15084582, ECO:0000269|PubMed:17217339,
CC       ECO:0000269|PubMed:17337443, ECO:0000269|PubMed:17878374,
CC       ECO:0000269|PubMed:17997719, ECO:0000269|PubMed:20400509,
CC       ECO:0000269|PubMed:24316379}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=650 uM for ATP (at pH 7.5) {ECO:0000269|PubMed:17312103};
CC         KM=1100 uM for substrate (at pH 7.5)
CC         {ECO:0000269|PubMed:17312103};
CC   -!- SUBUNIT: Associates with MYD88 and IRAK2 to form a ternary complex
CC       called the Myddosome. Once phosphorylated, IRAK4 dissociates from
CC       the receptor complex and then associates with the TNF receptor-
CC       associated factor 6 (TRAF6), IRAK1, and PELI1; this intermediate
CC       complex is required for subsequent NF-kappa-B activation. Direct
CC       binding of SMAD6 to PELI1 prevents complex formation and hence
CC       negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-
CC       mediated gene expression. Interacts with IL1RL1.
CC       {ECO:0000269|PubMed:11960013, ECO:0000269|PubMed:12496252,
CC       ECO:0000269|PubMed:16286016, ECO:0000269|PubMed:16951688,
CC       ECO:0000269|PubMed:17161373, ECO:0000269|PubMed:17312103,
CC       ECO:0000269|PubMed:24316379}.
CC   -!- INTERACTION:
CC       Q8K4B2:Irak3 (xeno); NbExp=4; IntAct=EBI-448378, EBI-646179;
CC       Q99836:MYD88; NbExp=9; IntAct=EBI-448378, EBI-447677;
CC       Q9HAT8:PELI2; NbExp=3; IntAct=EBI-448378, EBI-448407;
CC       P58753:TIRAP; NbExp=2; IntAct=EBI-448378, EBI-528644;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21325272}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NWZ3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NWZ3-2; Sequence=VSP_041556;
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- DISEASE: Recurrent isolated invasive pneumococcal disease 1 (IPD1)
CC       [MIM:610799]: Recurrent invasive pneumococcal disease (IPD) is
CC       defined as two episodes of IPD occurring at least 1 month apart,
CC       whether caused by the same or different serotypes or strains.
CC       Recurrent IPD occurs in at least 2% of patients in most series,
CC       making IPD the most important known risk factor for subsequent
CC       IPD. {ECO:0000269|PubMed:16950813}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: IRAK4 deficiency (IRAK4D) [MIM:607676]: Causes
CC       extracellular pyogenic bacterial and fungal infections in
CC       otherwise healthy children. {ECO:0000269|PubMed:12637671,
CC       ECO:0000269|PubMed:12925671, ECO:0000269|PubMed:17878374,
CC       ECO:0000269|PubMed:19663824, ECO:0000269|PubMed:21057262,
CC       ECO:0000269|PubMed:24316379}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. Pelle subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IRAK4base; Note=IRAK4 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/IRAK4base/";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/irak4/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF445802; AAM15772.1; -; mRNA.
DR   EMBL; AF155118; AAD42884.1; -; mRNA.
DR   EMBL; AY340964; AAR02360.1; -; mRNA.
DR   EMBL; AY340965; AAR02361.1; -; mRNA.
DR   EMBL; AY340966; AAR02362.1; -; mRNA.
DR   EMBL; AY340967; AAR02363.1; -; mRNA.
DR   EMBL; AK000528; BAA91232.1; -; mRNA.
DR   EMBL; AK299944; BAG61774.1; -; mRNA.
DR   EMBL; AY186092; AAN75440.1; -; Genomic_DNA.
DR   EMBL; AC093012; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC013316; AAH13316.1; -; mRNA.
DR   CCDS; CCDS44862.1; -. [Q9NWZ3-2]
DR   CCDS; CCDS8744.1; -. [Q9NWZ3-1]
DR   RefSeq; NP_001107654.1; NM_001114182.2. [Q9NWZ3-1]
DR   RefSeq; NP_001138728.1; NM_001145256.1. [Q9NWZ3-2]
DR   RefSeq; NP_001138729.1; NM_001145257.1. [Q9NWZ3-2]
DR   RefSeq; NP_001138730.1; NM_001145258.1. [Q9NWZ3-2]
DR   RefSeq; NP_057207.2; NM_016123.3. [Q9NWZ3-1]
DR   RefSeq; XP_005269000.1; XM_005268943.3. [Q9NWZ3-1]
DR   RefSeq; XP_005269001.1; XM_005268944.4. [Q9NWZ3-1]
DR   RefSeq; XP_005269002.1; XM_005268945.4. [Q9NWZ3-1]
DR   RefSeq; XP_005269004.1; XM_005268947.4. [Q9NWZ3-2]
DR   RefSeq; XP_005269005.1; XM_005268948.2. [Q9NWZ3-2]
DR   RefSeq; XP_005269006.1; XM_005268949.2. [Q9NWZ3-2]
DR   RefSeq; XP_006719501.1; XM_006719438.3. [Q9NWZ3-1]
DR   RefSeq; XP_006719502.1; XM_006719439.2. [Q9NWZ3-2]
DR   RefSeq; XP_011536733.1; XM_011538431.2. [Q9NWZ3-1]
DR   RefSeq; XP_011536734.1; XM_011538432.1. [Q9NWZ3-1]
DR   RefSeq; XP_011536735.1; XM_011538433.2. [Q9NWZ3-1]
DR   RefSeq; XP_016874879.1; XM_017019390.1. [Q9NWZ3-1]
DR   RefSeq; XP_016874880.1; XM_017019391.1. [Q9NWZ3-2]
DR   UniGene; Hs.138499; -.
DR   PDB; 2NRU; X-ray; 2.00 A; A/B/C/D=154-460.
DR   PDB; 2NRY; X-ray; 2.15 A; A/B/C/D=154-460.
DR   PDB; 2O8Y; X-ray; 2.40 A; A/B=163-460.
DR   PDB; 2OIB; X-ray; 2.00 A; A/B/C/D=160-460.
DR   PDB; 2OIC; X-ray; 2.40 A; A/B/C/D=160-460.
DR   PDB; 2OID; X-ray; 2.30 A; A/B/C/D=160-460.
DR   PDB; 3MOP; X-ray; 3.40 A; G/H/I/J=4-106.
DR   PDB; 4RMZ; X-ray; 2.20 A; A/B=154-460.
DR   PDB; 4U97; X-ray; 2.65 A; A/B=154-460.
DR   PDB; 4U9A; X-ray; 2.80 A; A/B=154-460.
DR   PDB; 4XS2; X-ray; 2.73 A; A/B/C/D=160-460.
DR   PDB; 4Y73; X-ray; 2.14 A; A/B/C/D=160-460.
DR   PDB; 4YO6; X-ray; 2.32 A; A/B/C/D=160-460.
DR   PDB; 4YP8; X-ray; 2.64 A; A/B/C/D=160-460.
DR   PDB; 4ZTL; X-ray; 2.39 A; A/B/C/D=160-460.
DR   PDB; 4ZTM; X-ray; 2.66 A; A/B/C/D=160-460.
DR   PDB; 4ZTN; X-ray; 2.23 A; A/B/C/D=160-460.
DR   PDB; 5KX7; X-ray; 2.80 A; A/B=160-460.
DR   PDB; 5KX8; X-ray; 2.67 A; A/B/C/D=160-460.
DR   PDBsum; 2NRU; -.
DR   PDBsum; 2NRY; -.
DR   PDBsum; 2O8Y; -.
DR   PDBsum; 2OIB; -.
DR   PDBsum; 2OIC; -.
DR   PDBsum; 2OID; -.
DR   PDBsum; 3MOP; -.
DR   PDBsum; 4RMZ; -.
DR   PDBsum; 4U97; -.
DR   PDBsum; 4U9A; -.
DR   PDBsum; 4XS2; -.
DR   PDBsum; 4Y73; -.
DR   PDBsum; 4YO6; -.
DR   PDBsum; 4YP8; -.
DR   PDBsum; 4ZTL; -.
DR   PDBsum; 4ZTM; -.
DR   PDBsum; 4ZTN; -.
DR   PDBsum; 5KX7; -.
DR   PDBsum; 5KX8; -.
DR   ProteinModelPortal; Q9NWZ3; -.
DR   SMR; Q9NWZ3; -.
DR   BioGrid; 119322; 26.
DR   DIP; DIP-31351N; -.
DR   IntAct; Q9NWZ3; 15.
DR   MINT; MINT-1383671; -.
DR   STRING; 9606.ENSP00000390651; -.
DR   BindingDB; Q9NWZ3; -.
DR   ChEMBL; CHEMBL3778; -.
DR   DrugBank; DB08590; 1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE.
DR   GuidetoPHARMACOLOGY; 2045; -.
DR   iPTMnet; Q9NWZ3; -.
DR   PhosphoSitePlus; Q9NWZ3; -.
DR   BioMuta; IRAK4; -.
DR   DMDM; 50401181; -.
DR   EPD; Q9NWZ3; -.
DR   MaxQB; Q9NWZ3; -.
DR   PaxDb; Q9NWZ3; -.
DR   PeptideAtlas; Q9NWZ3; -.
DR   PRIDE; Q9NWZ3; -.
DR   DNASU; 51135; -.
DR   Ensembl; ENST00000431837; ENSP00000390327; ENSG00000198001. [Q9NWZ3-2]
DR   Ensembl; ENST00000440781; ENSP00000408734; ENSG00000198001. [Q9NWZ3-2]
DR   Ensembl; ENST00000551736; ENSP00000446490; ENSG00000198001. [Q9NWZ3-1]
DR   Ensembl; ENST00000613694; ENSP00000479889; ENSG00000198001. [Q9NWZ3-1]
DR   GeneID; 51135; -.
DR   KEGG; hsa:51135; -.
DR   UCSC; uc001rnt.4; human. [Q9NWZ3-1]
DR   CTD; 51135; -.
DR   DisGeNET; 51135; -.
DR   GeneCards; IRAK4; -.
DR   HGNC; HGNC:17967; IRAK4.
DR   HPA; CAB016685; -.
DR   HPA; CAB022077; -.
DR   MalaCards; IRAK4; -.
DR   MIM; 606883; gene.
DR   MIM; 607676; phenotype.
DR   MIM; 610799; phenotype.
DR   neXtProt; NX_Q9NWZ3; -.
DR   OpenTargets; ENSG00000198001; -.
DR   Orphanet; 70592; Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency.
DR   PharmGKB; PA134914577; -.
DR   eggNOG; KOG1187; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063073; -.
DR   HOGENOM; HOG000116550; -.
DR   HOVERGEN; HBG066836; -.
DR   InParanoid; Q9NWZ3; -.
DR   KO; K04733; -.
DR   OMA; LAKCQHE; -.
DR   OrthoDB; EOG091G0YKT; -.
DR   PhylomeDB; Q9NWZ3; -.
DR   TreeFam; TF351380; -.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-446652; Interleukin-1 signaling.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5602680; MyD88 deficiency (TLR5).
DR   Reactome; R-HSA-5603037; IRAK4 deficiency (TLR5).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-975110; TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling.
DR   Reactome; R-HSA-975138; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation.
DR   Reactome; R-HSA-975155; MyD88 dependent cascade initiated on endosome.
DR   Reactome; R-HSA-975871; MyD88 cascade initiated on plasma membrane.
DR   SignaLink; Q9NWZ3; -.
DR   SIGNOR; Q9NWZ3; -.
DR   ChiTaRS; IRAK4; human.
DR   EvolutionaryTrace; Q9NWZ3; -.
DR   GenomeRNAi; 51135; -.
DR   PRO; PR:Q9NWZ3; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000198001; -.
DR   CleanEx; HS_IRAK4; -.
DR   ExpressionAtlas; Q9NWZ3; baseline and differential.
DR   Genevisible; Q9NWZ3; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005149; F:interleukin-1 receptor binding; IEA:Ensembl.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004672; F:protein kinase activity; EXP:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0001816; P:cytokine production; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0070498; P:interleukin-1-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0002446; P:neutrophil mediated immunity; IMP:UniProtKB.
DR   GO; GO:1990266; P:neutrophil migration; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:MGI.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IBA:GO_Central.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0034162; P:toll-like receptor 9 signaling pathway; TAS:Reactome.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:UniProtKB.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR017428; IL-1_rcpt-assoc_kin4.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF038189; IRAK4; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Immunity; Innate immunity; Kinase;
KW   Magnesium; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    460       Interleukin-1 receptor-associated kinase
FT                                4.
FT                                /FTId=PRO_0000086035.
FT   DOMAIN       20    104       Death.
FT   DOMAIN      186    454       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     192    200       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     313    316       ATP.
FT   ACT_SITE    311    311       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     213    213       ATP.
FT   BINDING     329    329       ATP.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES      34     34       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     342    342       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17312103,
FT                                ECO:0000269|Ref.31}.
FT   MOD_RES     345    345       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17161373,
FT                                ECO:0000269|PubMed:17312103,
FT                                ECO:0000269|Ref.31}.
FT   MOD_RES     346    346       Phosphoserine.
FT                                {ECO:0000269|PubMed:17161373,
FT                                ECO:0000269|PubMed:17312103}.
FT   VAR_SEQ       1    124       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_041556.
FT   VARIANT       5      5       I -> V (polymorphism; no effect on
FT                                inhibition of NF-kappa-B activation; no
FT                                effect on interaction with MYD88;
FT                                dbSNP:rs56312115).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_040588.
FT   VARIANT      12     12       R -> C (in IRAK4D; no effect on
FT                                inhibition of NF-kappa-B complex
FT                                activation; loss of interaction with
FT                                MYD88; decreases protein stability;
FT                                dbSNP:rs377584435).
FT                                {ECO:0000269|PubMed:17878374,
FT                                ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_072888.
FT   VARIANT      20     20       R -> W (polymorphism; increases
FT                                inhibition of NF-kappa-B complex
FT                                activation; decreases interaction with
FT                                MYD88; decreases protein stability;
FT                                dbSNP:rs143625818).
FT                                {ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_072889.
FT   VARIANT      26     26       I -> T (polymorphism; no effect on
FT                                inhibition of NF-kappa-B activation; no
FT                                effect on interaction with MYD88;
FT                                dbSNP:rs138116867).
FT                                {ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_072890.
FT   VARIANT      39     39       I -> V (polymorphism; no effect on
FT                                inhibition of NF-kappa-B activation; no
FT                                effect on interaction with MYD88;
FT                                dbSNP:rs113588409).
FT                                {ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_072891.
FT   VARIANT      98     98       S -> R (polymorphism; no effect on
FT                                inhibition of NF-kappa-B activation; no
FT                                effect on interaction with MYD88;
FT                                dbSNP:rs4251469).
FT                                {ECO:0000269|PubMed:24316379,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019354.
FT   VARIANT     298    298       G -> D (in IRAK4D; decreases inhibition
FT                                of NF-kappa-B complex activation; impairs
FT                                neutrophil migration and phagocytosis;
FT                                dbSNP:rs568782766).
FT                                {ECO:0000269|PubMed:19663824,
FT                                ECO:0000269|PubMed:21057262,
FT                                ECO:0000269|PubMed:24316379}.
FT                                /FTId=VAR_072892.
FT   VARIANT     355    355       M -> V (in dbSNP:rs142376871).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040589.
FT   VARIANT     390    390       H -> R (in dbSNP:rs4251583).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019355.
FT   VARIANT     391    391       R -> H (found in a patient with IRAK4D in
FT                                association with C-12; probable neutral
FT                                polymorphism; dbSNP:rs55944915).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:17878374}.
FT                                /FTId=VAR_040590.
FT   VARIANT     428    428       A -> T (in dbSNP:rs4251545).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019356.
FT   MUTAGEN     213    213       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15084582}.
FT   CONFLICT     81     81       V -> A (in Ref. 1; AAM15772).
FT                                {ECO:0000305}.
FT   CONFLICT    432    432       V -> G (in Ref. 2; AAD42884).
FT                                {ECO:0000305}.
FT   CONFLICT    437    437       L -> R (in Ref. 2; AAD42884).
FT                                {ECO:0000305}.
FT   CONFLICT    444    444       R -> S (in Ref. 2; AAD42884).
FT                                {ECO:0000305}.
FT   CONFLICT    451    451       Q -> H (in Ref. 2; AAD42884).
FT                                {ECO:0000305}.
FT   HELIX        11     13       {ECO:0000244|PDB:3MOP}.
FT   HELIX        16     26       {ECO:0000244|PDB:3MOP}.
FT   HELIX        31     38       {ECO:0000244|PDB:3MOP}.
FT   STRAND       42     48       {ECO:0000244|PDB:3MOP}.
FT   HELIX        50     57       {ECO:0000244|PDB:3MOP}.
FT   HELIX        58     60       {ECO:0000244|PDB:3MOP}.
FT   TURN         61     63       {ECO:0000244|PDB:3MOP}.
FT   HELIX        66     73       {ECO:0000244|PDB:3MOP}.
FT   TURN         74     77       {ECO:0000244|PDB:3MOP}.
FT   HELIX        81     89       {ECO:0000244|PDB:3MOP}.
FT   TURN         90     92       {ECO:0000244|PDB:3MOP}.
FT   HELIX        94    100       {ECO:0000244|PDB:3MOP}.
FT   STRAND      102    104       {ECO:0000244|PDB:3MOP}.
FT   STRAND      166    168       {ECO:0000244|PDB:2OIB}.
FT   HELIX       170    176       {ECO:0000244|PDB:2NRU}.
FT   TURN        177    180       {ECO:0000244|PDB:2NRU}.
FT   TURN        185    188       {ECO:0000244|PDB:2NRU}.
FT   STRAND      191    194       {ECO:0000244|PDB:2NRU}.
FT   STRAND      196    207       {ECO:0000244|PDB:2NRU}.
FT   STRAND      209    215       {ECO:0000244|PDB:2NRU}.
FT   STRAND      218    220       {ECO:0000244|PDB:4Y73}.
FT   TURN        223    225       {ECO:0000244|PDB:2NRU}.
FT   HELIX       226    239       {ECO:0000244|PDB:2NRU}.
FT   STRAND      248    252       {ECO:0000244|PDB:2NRU}.
FT   STRAND      254    257       {ECO:0000244|PDB:2NRU}.
FT   STRAND      259    263       {ECO:0000244|PDB:2NRU}.
FT   HELIX       270    275       {ECO:0000244|PDB:2NRU}.
FT   HELIX       277    279       {ECO:0000244|PDB:2NRU}.
FT   HELIX       285    304       {ECO:0000244|PDB:2NRU}.
FT   HELIX       314    316       {ECO:0000244|PDB:2NRU}.
FT   STRAND      317    319       {ECO:0000244|PDB:2NRU}.
FT   STRAND      325    327       {ECO:0000244|PDB:2NRU}.
FT   STRAND      349    351       {ECO:0000244|PDB:4U97}.
FT   HELIX       352    354       {ECO:0000244|PDB:2NRU}.
FT   HELIX       357    360       {ECO:0000244|PDB:2NRU}.
FT   HELIX       367    382       {ECO:0000244|PDB:2NRU}.
FT   STRAND      391    395       {ECO:0000244|PDB:2NRU}.
FT   HELIX       398    404       {ECO:0000244|PDB:2NRU}.
FT   HELIX       410    413       {ECO:0000244|PDB:2NRU}.
FT   HELIX       423    436       {ECO:0000244|PDB:2NRU}.
FT   TURN        441    443       {ECO:0000244|PDB:2NRU}.
FT   HELIX       447    457       {ECO:0000244|PDB:2NRU}.
SQ   SEQUENCE   460 AA;  51530 MW;  6C8156ADF25FF81E CRC64;
     MNKPITPSTY VRCLNVGLIR KLSDFIDPQE GWKKLAVAIK KPSGDDRYNQ FHIRRFEALL
     QTGKSPTSEL LFDWGTTNCT VGDLVDLLIQ NEFFAPASLL LPDAVPKTAN TLPSKEAITV
     QQKQMPFCDK DRTLMTPVQN LEQSYMPPDS SSPENKSLEV SDTRFHSFSF YELKNVTNNF
     DERPISVGGN KMGEGGFGVV YKGYVNNTTV AVKKLAAMVD ITTEELKQQF DQEIKVMAKC
     QHENLVELLG FSSDGDDLCL VYVYMPNGSL LDRLSCLDGT PPLSWHMRCK IAQGAANGIN
     FLHENHHIHR DIKSANILLD EAFTAKISDF GLARASEKFA QTVMTSRIVG TTAYMAPEAL
     RGEITPKSDI YSFGVVLLEI ITGLPAVDEH REPQLLLDIK EEIEDEEKTI EDYIDKKMND
     ADSTSVEAMY SVASQCLHEK KNKRPDIKKV QQLLQEMTAS
//
